5 stories mentioning ASX:EIQUpdated 23m ago
Every FINWIRES story that references ASX:EIQ, newest first.
Echo IQ (ASX:EIQ) appointed Matthew Dodds as chief financial officer, effective Wednesday, according to a Tuesday filing with the Australian bourse.Dodds most recently served as senior vice president of corporate development and information technology at LivaNova, the filing added.
(Updates to add stock movement in the headline and the last paragraph)Echo IQ (ASX:EIQ) struck a research collaboration agreement with Mayo Clinic to evaluate the ability of Echo's proprietary artificial intelligence platform to estimate cardiac risk in cancer patients, according to a Friday filing with the Australian bourse.The research will assess the platform's ability to generate predictive risk scores for heart failure based on echocardiogram data for oncology patients.The study will also aim to assess the applicability of the AI platform in a "large and clinically important patient population beyond its current cardiovascular applications," the company said.The company's shares fell 4% in recent Friday trade.
Echo IQ (ASX:EIQ) struck a research collaboration agreement with Mayo Clinic to evaluate the ability of Echo's proprietary artificial intelligence platform to estimate cardiac risk in cancer patients, according to a Friday filing with the Australian bourse.The research will assess the platform's ability to generate predictive risk scores for heart failure based on echocardiogram data for oncology patients.The study will also aims to assess the applicability of the AI platform in a "large and clinically important patient population beyond its current cardiovascular applications," the company said.
Echo IQ (ASX:EIQ) said the usage of EchoSolv AS, its decision support software for the assessment of severe aortic stenosis, a progressive heart condition, was up around 131% quarter over quarter in the three months ended March 31, according to a Thursday Australian bourse filing.The company said 9,220 echocardiograms were processed in the first quarter, from 3,992 in the December 2025 quarter.The company is progressing its heart failure clinical decision support product, EchoSolv HF, through the US Food and Drug Administration 510(k) pathway.It is also focused on securing major US hospital group signings and advancing regulatory clearance via Australia's Therapeutic Goods Administration, per the filing.Echo IQ's shares fell nearly 2% in recent trading on Thursday.
Echo IQ (ASX:EIQ) deployed EchoSolv AS, its artificial intelligence-based decision support software for the assessment of severe aortic stenosis, into the Mount Sinai Health System in New York, according to a Tuesday filing with the Australian bourse.The company continues to engage with prospective hospitals in the US regarding potential opportunities for the product, the filing said.
